Scilex Holding Company (SCLX)
NASDAQ: SCLX · IEX Real-Time Price · USD
0.853
-0.003 (-0.32%)
May 2, 2024, 1:32 PM EDT - Market open
Scilex Holding Company Revenue
In the year 2023, Scilex Holding Company had annual revenue of $46.74M with 22.90% growth. Revenue in the quarter ending December 31, 2023 was $13.46M with 12.95% year-over-year growth.
Revenue (ttm)
$46.74M
Revenue Growth
+22.90%
P/S Ratio
3.04
Revenue / Employee
$445,171
Employees
105
Market Cap
142.23M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 46.74M | 8.71M | 22.90% |
Dec 31, 2022 | 38.03M | 6.72M | 21.45% |
Dec 31, 2021 | 31.32M | 7.76M | 32.92% |
Dec 31, 2020 | 23.56M | 2.53M | 12.01% |
Dec 31, 2019 | 21.03M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Outset Medical | 130.38M |
Repare Therapeutics | 51.13M |
Biodesix | 49.09M |
Zomedica | 25.19M |
ClearPoint Neuro | 23.96M |
Seer, Inc. | 16.66M |
Syros Pharmaceuticals | 9.94M |
I-Mab | 3.90M |
SCLX News
- 6 days ago - Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering - GlobeNewsWire
- 8 days ago - Scilex Holding Company Announces $15 Million Registered Direct Offering - GlobeNewsWire
- 16 days ago - Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses - GlobeNewsWire
- 23 days ago - Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool - GlobeNewsWire
- 5 weeks ago - Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend - GlobeNewsWire
- 6 weeks ago - Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients - GlobeNewsWire
- 6 weeks ago - Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed - GlobeNewsWire
- 6 weeks ago - Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba® - GlobeNewsWire